linjc16/ctgov huggingface dataset:
Finger Imaging to Detect Blood Flow in the Fingertips

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to develop a small, easily used device to detect a person's blood flow in their fingertips.

Detailed Description
-----------------
To develop a hand held touch-pad device for identification of individuals, to help with banking and, possibly for detection of anxiety. This is done by their fingerprint and, other digital anatomy and vascular biometrics.

Official Title
-----------------
Finger Imaging and Biometric System

Conditions
-----------------
Capillary Permeability

Intervention / Treatment
-----------------
* Procedure: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult male and female who can give informed consent Exclusion Criteria: Under the age of 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Ultrasound Imaging of fingertips | Procedure: Ultrasound<br>* Ultrasound scanning of fingertips for assessment of possible imaging modes with Gray scale ultrasound, color flow vascularity imaging, and color flow vascularity imaging before and after exercise.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To develop a new type of electronic hand held device, that will demonstrate the image quality comparable to existing devices based on optical techniques. |  | 2002-2011 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vascularity, fingertips
Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether intraocular injection of triamcinolone is effective in the treatment of macular edema in acute branch retinal vein occlusion.

Detailed Description
-----------------
Intravitreal triamcinolone has recently been shown to have beneficial effect on chronic macular edema due to vein occlusion and preventive effect on neovascularization. Hypothetically, prevention of macular derangement by reducing the amount of edema from early phase after occlusion until restoration of collaterals seems to be helpful in these eyes. To our knowledge, no prospective randomized clinical trial, considering both macular changes and preventive effect on neovascularization has been published for intravitreal triamcinolone in acute branch retinal vein occlusion.

Conditions
-----------------
Branch Retinal Vein Occlusion

Intervention / Treatment
-----------------
* Drug: Triamcinolone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eyes suffering from branch retinal vein occlusion with less than 2 months duration. Exclusion Criteria: Monocularity, Previous intraocular surgery or laser therapy Glaucoma or ocular hypertension Significant media opacity Existence of traction on the macula Visual acuity ≥20/40 Signs of chronicity (such as cilioretinal and/or retinal shunt vessels)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Triamcinolone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Central macular thickness |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity |  |  | 
| Retinal neovascularization |  |  | 
| Intraocular pressure |  |  | 
| Cataract progression |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Macular edema, Branch retinal vein occlusion, Intravitreal triamcinolone, Macular thickness, Retinal neovascularization
A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the efficacy and safety of co-administration of DWC202206 and DWC202207 in patients with concomitant hypertension and hyperlipidemia.

Detailed Description
-----------------
The study design is a randomized, double-blind, multicenter clinical trial. The patients were randomly assigned to each group. Primary endpoint was the change of MSSBP based on baseline between Treatment arm and control 1 arm and the change of LDL-C based on baseline between arm and control 2 arm.

Official Title
-----------------
A Randomized, Double-blind, Multicenter Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Hypertension and Dyslipidemia

Conditions
-----------------
Hypertension, Hyperlipidemias

Intervention / Treatment
-----------------
* Drug: (D) DWC202206
* Drug: (D) DWC202207
* Drug: (P) DWC202206
* Drug: (P) DWC202207


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 19 to 80 years Patients with hypertension and hyperlipidemias Exclusion Criteria: Orthostatic hypotension History of ventricular tachycardia, atrial fibrillation Uncontrolled diabetes mellitus

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: (D) DWC202206 + DWC202207<br> | Drug: (D) DWC202206<br>* Drug of DWC202206 A mg<br>Drug: (D) DWC202207<br>* Drug of DWC202207 B/C mg<br>|
| Active Comparator: (P+D) DWC202206 + DWC202207<br> | Drug: (D) DWC202207<br>* Drug of DWC202207 B/C mg<br>Drug: (P) DWC202206<br>* Placebo of DWC202206 A mg<br>|
| Active Comparator: (D+P) DWC202206 + DWC202207<br> | Drug: (D) DWC202206<br>* Drug of DWC202206 A mg<br>Drug: (P) DWC202207<br>* Placebo of DWC202207 B/C mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baseline between treatment arm and control 1 arm |  | 8 weeks | 
| The change of LDL-C based on baseline between treatment arm and control 2 arm |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baseline between treatment arm and control 1 arm |  | 4 weeks | 
| The change of LDL-C based on baseline between treatment arm and control 2 arm |  | 4 weeks |
Assessment Vitamin D Analogues Intake Pathways on the Proteins Which Involved in Metabolic Rate in Obese Subjects

Study Overview
=================
Brief Summary
-----------------
The aim of this double blind clinical trial study is to investigate whether alphacalcidol treatment in obese subjects can affect the resting metabolic rate. Moreover, the investigators will evaluate the pathways of Nesfatin-1, Peroxisome proliferator-activated receptor gamma (PPARγ) and eroxisome proliferator-activated receptor- coactivator-1 α (PGC1α) protein which may lead to change in metabic rate following treatment with either alphacalcidol or placebo.

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Dietary Supplement: Placebo
* Dietary Supplement: Vitamin D analogue


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 22-52 years Body mass index equal or more than 30 Exclusion Criteria: Acute or chronic inflammatory disease History of hypertension Alcohol or drug abuse History of any condition affecting inflammatory markers Thyroid diseases Malignancies Current smoking Diabetes mellitus Sustained hypertension Heart failure Acute or chronic infections Hepatic or renal diseases Use of PPARγ agonist drug

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 52 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitamin D analogue<br>1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram. | Dietary Supplement: Vitamin D analogue<br>* 1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks<br>* Other names: 1-α hydroxyvitamin D3;|
| Placebo Comparator: Placebo<br>Corn oil pearl Capsules 1 gram | Dietary Supplement: Placebo<br>* Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks<br>* Other names: corn oil capsule;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resting Metabolic Rate | Measurement by indirect calorimetry. | Change from baseline to 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes of Nesfatin-1, PPARγ and PGC1α protein levels | Measurement by ELISA kit | Change from baseline to 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vitamin D analogues, Resting Metabolic rate, obesity
Liver Fibrosis in Peri-menopausal Women

Study Overview
=================
Brief Summary
-----------------
This is a prospective observational study in a single medical center. The aim is to evaluate the status of fibrosis and steatosis of liver parenchyma in peri-menopausal women using noninvasive methods of vibration-controlled transient elastography (VCTE) with controlled attenuation parameter (CAP) and serum biomarkers. Recruitment period: 2018/08/01 to 2019/07/31 Patient number: 200 females Inclusion criteria: Females, age of 46-55 years Willing and able to comply with the study requirements Willing and able to provide written informed consent to participate in the study Exclusion criteria: Unable to complete the noninvasive procedure of VCET and CAP Unwilling to provide written informed consent to participate in the study Laboratory tests and examinations: Baseline and two follow-up visits (every 6 months): Blood pressure BW, BH, waist circumference, BMI Complete blood cell (CBC) count Albumin, AST, ALT, alkaline phosphatase, total bilirubin, r-GT, uric acid, hsCRP Sugar (fasting), HbA1c, insulin, HOMA-IR DM lipid profiles, adiponectin, leptin Liver ultrasound, FibroScan touch 520 FSH, Estrodiol (E2), LH TSH, free T4 HBsAg, anti-HCV, HBV DNA, HCV RNA, HBsAg quantification, HBV genotype (if HBsAg or anti-HCV positive) ANA, Anti-mitochondrial antibody Review history of drug and menstruation cycles

Official Title
-----------------
Nonalcoholic Fatty Liver Disease and Associated Liver Fibrosis in Peri-menopausal Women

Conditions
-----------------
Menopause, Nonalcoholic Steatohepatitis, Liver Fibroses

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females, age of 46-55 years Willing and able to comply with the study requirements Willing and able to provide written informed consent to participate in the study Exclusion Criteria: Unable to complete the noninvasive procedure of VCET and CAP Unwilling to provide written informed consent to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 46 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pre-menopause<br> | |
| post-menopause<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The impact of estrogen level on liver steatosis by FibroScan touch 520 | The association of estrogen level with the severity of liver steatosis. | 1 year | 
| The impact of estrogen level on liver fibrosis by FibroScan touch 520 | The association of estrogen level with the severity of liver fibrosis. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Menopause, Nonalcoholic steatohepatitis, Liver fibrosis, Hormone
Clinical Significance of 64-slice Multidetector Coronary CT Angiography to Evaluate the Prevalence and Severity of Coronary Artery Disease in Renal Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the clinical usefulness of 64-slice multidetector coronary CT angiography (MDCTA) in renal transplant recipients who had no previous coronary artery disease (CAD). Primary endpoint is to assess the prevalence and severity of coronary artery disease in patients post-transplant 6 to 12 months. CAD can be diagnosed noninvasively with similar accuracy of coronary angiography using MDCTA. Early detection and intervention of CAD may provide survival benefit in renal transplant recipients.

Conditions
-----------------
Kidney Transplant Recipient

Intervention / Treatment
-----------------
* Other: 64-slice Multidetector coronary CT angiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 40 yrs renal transplant recipient at post-transplant 6 to 12 months stable graft renal function: CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation ≥45 mL/min/1.75m2 patients who had no previous CAD Exclusion Criteria: unstable graft renal function History of acute kidney injury within 3 months Allergic history to contrast agent Irregular heart beat Multiorgan transplant recipients Pregnancy Patients who do not consent to this study

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MDCTA<br> | Other: 64-slice Multidetector coronary CT angiography<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of coronary artery disease |  | at post-transplant 6 to 12 months. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| severity of coronary artery disease |  | at post-transplant 6 to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multidetector coronary CT angiography, renal transplantation
Comparison Between Auto CPAP and Fixed CPAP in Chinese Patients With OSA

Study Overview
=================
Brief Summary
-----------------
AutoCPAP would lead to better compliance than FixCPAP

Detailed Description
-----------------
A prospective, randomized crossover cohort. Study subjects consisted of patients newly diagnosed with obstructive sleep apnea (OSA) confirmed with sleep study. All are CPAP naïve. Randomization: Arm 1: auto CPAP sleep study then auto CPAP for 2 months Arm 2: fixed CPAP titration then fixed CPAP for 2 months Then switch over to the other arm Trial end after 4 months, compliance and other parameters would be compared between two arms as described in the endpoint session.

Official Title
-----------------
Comparison of Auto-Continuous Positive Airway Pressure Device(Auto-CPAP) With Conventional Fixed CPAP in Chinese Patients With Obstructive Sleep Apnea (OSA)

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Device: AutoCPAP
* Device: FixCPAP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All subjects should be CPAP naïve. OSA confirmed with sleep study Presence of daytime symptoms with excessive daytime sleepiness Age between 18 to 65 RDI greater than 30 Agreed to participate in trial with informed consent signed Exclusion Criteria: Patients not suitable to nasal CPAP because of facial abnormality leading to poor mask fitting. Patients with known COPD with type II failure Patients with known heart failure. Patients with predominant central sleep apnea. Patients need bilevel positive airway pressure ventilation. Patients refusing to participate the trial. Patients have difficulty to follow up regularly. patients with untreated or under treatment of hypothyroidism

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: AutoCPAP|nan|
|Device: FixCPAP|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the compliance of auto-CPAP and fixed CPAP in terms of CPAP usage hours. |  |  | 
| To compare the clinical efficacy of auto-CPAP and fixed CPAP in terms of pressure level to abolish OSA, Epworth sleepiness scale and quality of life questionnaire. |  |  | 
| To compare patient acceptance of the different type of treatment. |  |  |
Cystic Fibrosis Adherence Study

Study Overview
=================
Brief Summary
-----------------
This study aims to assess the role of some factors which can influence the chest physiotherapy adherence in adult with cystic fibrosis. At first, we are going to try to consider the adherence of chest physiotherapy. Then, after dividing the patients into two groups - adherent or not adherent - we will attempt to identify the factors which can influence this adherence. It consists in a short questionnaire that the patient will fill during usual visits. The hypothesis is that the following factors can play a role in adherence of chest physiotherapy: Age Age of diagnostic Sex Fev1 Number of antibiotic course Anxiety/depression Work time Socio-professional category Individual situation Physiotherapy with liberal physiotherapist and transport time Sport practice Family support Feeling of work time burden Feeling of physiotherapy efficiency Feeling of physiotherapy burden

Official Title
-----------------
Study of the Adherence to Chest Physiotherapy in Patients With Cystic Fibrosis (CF) at the Adult CF Center in Lyon

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: respiratory symptoms subnormal respiratory function (FEV1 < 80%) without lung transplant Exclusion Criteria: lung transplantation approach

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adherent patient<br>This group is composed of adherent patients to the chest physiotherapy based on the number of chest physiotherapy session per week. | Other: Questionnaire<br>* Short questionnaire that can be completed during the usual consultation.<br>|
| Not-adherent patient<br>This group is composed of not-adherent patients to the chest physiotherapy based on the number of chest physiotherapy session per week. | Other: Questionnaire<br>* Short questionnaire that can be completed during the usual consultation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantity of chest physiotherapy | If the quantity of chest physiotherapy alone (do well) or/and with physiotherapist is above or egal at 3 per week, the patient is adherent If the quantity of chest physiotherapy is under 3 sessions per week, the patient is not- adherent Then we measure the proportion of each group for each secondary factors. | 8 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cystic Fibrosis, Adherence to chest physiotherapy